Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.060
-0.440 (-12.57%)
At close: Nov 13, 2025, 4:00 PM EST
3.110
+0.050 (1.63%)
After-hours: Nov 13, 2025, 4:58 PM EST
Atea Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Atea Pharmaceuticals stock has a target of 6.00, which predicts a 96.08% increase from the current stock price of 3.06.
Price Target: $6.00 (+96.08%)
Analyst Consensus: Hold
* Price targets were last updated on Apr 11, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Atea Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $6.2 → $6 | Hold | Maintains | $6.2 → $6 | +96.08% | Apr 11, 2025 |
| Morgan Stanley | Morgan Stanley | Sell → Hold Upgrades $2 → $6.88 | Sell → Hold | Upgrades | $2 → $6.88 | +124.84% | Aug 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Aug 10, 2023 |
| JP Morgan | JP Morgan | Hold Maintains $12 → $8 | Hold | Maintains | $12 → $8 | +161.44% | Mar 16, 2023 |
| SVB Leerink | SVB Leerink | Hold Maintains $8 → $6 | Hold | Maintains | $8 → $6 | +96.08% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.75
from -2.00
EPS Next Year
-1.74
from -1.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.81 | -1.80 | |
| Avg | -1.75 | -1.74 | |
| Low | -1.69 | -1.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.